2024
OncoSexome: the landscape of sex-based differences in oncologic diseases
Shen X, Zhang Y, Li J, Zhou Y, Butensky S, Zhang Y, Cai Z, DeWan A, Khan S, Yan H, Johnson C, Zhu F. OncoSexome: the landscape of sex-based differences in oncologic diseases. Nucleic Acids Research 2024, gkae1003. PMID: 39535034, DOI: 10.1093/nar/gkae1003.Peer-Reviewed Original Research16S rRNA target sequencing of human tumors validates findings of Lachnoclostridium abundance in human melanomas that are heavily CD8+ T-cell infiltrated
Lu L, Johnson C, Khan S, Kluger H. 16S rRNA target sequencing of human tumors validates findings of Lachnoclostridium abundance in human melanomas that are heavily CD8+ T-cell infiltrated. European Journal Of Cancer 2024, 213: 115084. PMID: 39477777, DOI: 10.1016/j.ejca.2024.115084.Peer-Reviewed Original ResearchCharting the metabolic biogeography of the colorectum in cancer: challenging the right sided versus left sided classification
Jain A, Morris M, Berardi D, Arora T, Domingo-Almenara X, Paty P, Rattray N, Kerekes D, Lu L, Khan S, Johnson C. Charting the metabolic biogeography of the colorectum in cancer: challenging the right sided versus left sided classification. Molecular Cancer 2024, 23: 211. PMID: 39342363, PMCID: PMC11438248, DOI: 10.1186/s12943-024-02133-5.Peer-Reviewed Original ResearchConceptsRectal cancerNormal mucosaMetabolite abundancePatient-matched tumorTumor-specific metabolitesMetabolic heterogeneityPatient survivalRectosigmoid colonSigmoid colonAnatomic subsitePatient-matched normal mucosaTransverse colonMetabolomic profilesAscending colonCRC biomarkersMetabolome DatabaseDescending colonMetabolite changesLeft-sidedRight-sidedColorectumRisk factorsMetabolome mapCancerTumorHuman AKR1C3 binds agonists of GPR84 and participates in an expanded polyamine pathway
Dudkina N, Park H, Song D, Jain A, Khan S, Flavell R, Johnson C, Palm N, Crawford J. Human AKR1C3 binds agonists of GPR84 and participates in an expanded polyamine pathway. Cell Chemical Biology 2024 PMID: 39163853, DOI: 10.1016/j.chembiol.2024.07.011.Peer-Reviewed Original ResearchHuman aldo-keto reductase family 1 member C3Mammalian fatty acid synthaseDNA double-strand break responseDouble-strand break responseAldo-keto reductase family 1 member C3Associated with poor prognosisPolyamine pathwayFatty acid synthesisFatty acid synthaseAcid synthaseAKR1C3 activityPoor prognosisBiochemical roleAcid synthesisClinical significanceLigand screeningFerroptosis resistanceDNA damageAKR1C3Metabolic diseasesDiverse cancersDNANADPHAgonists of GPR84GPR84Asparagine synthetase and G‐protein coupled estrogen receptor are critical responders to nutrient supply in KRAS mutant colorectal cancer
Lu L, Zhang Q, Aladelokun O, Berardi D, Shen X, Marin A, Garcia‐Milian R, Roper J, Khan S, Johnson C. Asparagine synthetase and G‐protein coupled estrogen receptor are critical responders to nutrient supply in KRAS mutant colorectal cancer. International Journal Of Cancer 2024, 156: 52-68. PMID: 39039782, PMCID: PMC11537827, DOI: 10.1002/ijc.35104.Peer-Reviewed Original ResearchG protein-coupled estrogen receptor 1KRAS mutant colorectal cancerAsparagine synthetase expressionMutant colorectal cancerColorectal cancerAsparagine synthetaseG-protein coupled estrogen receptor 1 expressionG protein-coupled estrogen receptorWild-typeAssociated with poor overall survivalAdvanced stage tumorsKRAS wild-typeProtective effect of estradiolEffects of estradiolPoor overall survivalEstrogen receptor 1Expression of asparagine synthetasePresence of estradiolIncreased caspase-3 activityDepletion inhibited cell growthColon cancer cohortNutrient supplyAdvanced tumorsOverall survivalStage tumorsAsparagine synthetase and G-protein coupled estrogen receptor are critical responders to nutrient supply in KRAS mutant colorectal cancer
Lu, L, Zhang Q, Shen X, Zhen P, Marin P, Garcia-Milian R, Roper J, Khan S, Johnson C. In press at International Journal of Cancer.Peer-Reviewed Original Research In PressGrowth characteristics of HCT116 xenografts lacking asparagine synthetase vary according to sex
Aladelokun O, Lu L, Zheng J, Yan H, Jain A, Gibson J, Khan S, Johnson C. Growth characteristics of HCT116 xenografts lacking asparagine synthetase vary according to sex. Human Genomics 2024, 18: 67. PMID: 38886847, PMCID: PMC11184737, DOI: 10.1186/s40246-024-00635-3.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAspartate-Ammonia LigaseCarbon-Nitrogen Ligases with Glutamine as Amide-N-DonorCell ProliferationColorectal NeoplasmsFemaleGene Expression Regulation, NeoplasticHCT116 CellsHeterograftsHumansMaleMiceReceptors, EstrogenReceptors, G-Protein-CoupledSex FactorsXenograft Model Antitumor AssaysConceptsFemale tumor-bearing miceFemale CRC patientsTumor-bearing miceCRC patientsTumor growthInferior survivalAssociated with inferior survivalMetabolic reprogrammingG protein-coupled estrogen receptorTriggering metabolic reprogrammingSustained tumor growthSuppressed tumor growthExpression of asparagine synthetaseCancer cell linesBackgroundSex-related differencesSurvival improvementImpact of sexFemale miceEstrogen receptorCancer growthTranslational relevanceRewiring of metabolic pathwaysCancer burdenMetabolic pathwaysAsparagine synthetaseReasonable expansion of surgical candidates for HCC treatment
Butensky S, Billingsley K, Khan S. Reasonable expansion of surgical candidates for HCC treatment. Clinical Liver Disease 2024, 23: e0153. PMID: 38720794, PMCID: PMC11078523, DOI: 10.1097/cld.0000000000000153.Peer-Reviewed Original ResearchDifferent patient populations: In reply to Higashi, et al.
Khan SA, Kerekes D. JAMA Oncology 2024. 10.1001/jamaoncol.2024.1566.Commentaries, Editorials and LettersDifferent patient populations: In reply to Yorio
Khan SA, Kerekes D. JAMA Oncology 2024. doi: 10.1001/jamaoncol.2023.5932Commentaries, Editorials and LettersImmunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
Kerekes D, Frey A, Prsic E, Tran T, Clune J, Sznol M, Kluger H, Forman H, Becher R, Olino K, Khan S. Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US. JAMA Oncology 2024, 10: 342-351. PMID: 38175659, PMCID: PMC10767643, DOI: 10.1001/jamaoncol.2023.6025.Peer-Reviewed Original ResearchNon-small cell lung cancerEnd of lifeMonth of deathImmunotherapy initiationCohort studyMAIN OUTCOMEStage IV non-small cell lung cancerCharlson-Deyo comorbidity indexHigh metastatic burdenInitiation of immunotherapyNational prescribing patternsRisk-adjusted patientsImmune checkpoint inhibitorsRetrospective cohort studyStage IV melanomaPercentage of patientsHigh-volume centersLocation of metastasesLow-volume centersOdds of deathCell lung cancerNational Clinical DatabaseLow-volume facilitiesDrug Administration approvalCheckpoint inhibitorsImmunotherapy utilization in stage IIIA melanoma: less may be more
Frey A, Kerekes D, Khan S, Tran T, Kluger H, Clune J, Ariyan S, Sznol M, Ishizuka J, Olino K. Immunotherapy utilization in stage IIIA melanoma: less may be more. Frontiers In Oncology 2024, 14: 1336441. PMID: 38380358, PMCID: PMC10876869, DOI: 10.3389/fonc.2024.1336441.Peer-Reviewed Original ResearchStage IIIA melanomaHigh-volume centersRisk-adjusted survivalLow-volume centersImmunotherapy utilizationAdjuvant immunotherapyStage IIIATreatment of stage III melanomaAcademic centersMultivariable Cox proportional hazards regressionStage III melanomaNational Cancer DatabaseStage III diseaseFactors associated with receiptCox proportional hazards regressionCompare patient outcomesProportional hazards regressionIII melanomaImmunotherapy receiptReceiving immunotherapyIII diseaseImmunotherapy agentsOverall survivalSurvival benefitAdjuvant treatmentDigital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma
Su D, Schoenfeld D, Wael I, Cabrejo R, Baumann R, Rimm D, Khan SA, Halaban R, Kluger H, Olino K, Galan A, Clune J, Kluger H, Clune J. Journal of ImmunoTherapy of Cancer 2024.12(3), e008646. https://doi.org/10.1136/jitc-2023-008646Peer-Reviewed Original ResearchCell surface RNAs control neutrophil recruitment
Zhang N, Tang W, Torres L, Wang X, Ajaj Y, Zhu L, Luan Y, Zhou H, Wang Y, Zhang D, Kurbatov V, Khan S, Kumar P, Hidalgo A, Wu D, Lu J. Cell surface RNAs control neutrophil recruitment. Cell 2024, 187: 846-860.e17. PMID: 38262409, PMCID: PMC10922858, DOI: 10.1016/j.cell.2023.12.033.Peer-Reviewed Original ResearchConceptsCell surfaceMammalian homologOuter cell surfaceRNA transportGlycan modificationsMammalian cellsSID-1Cellular functionsRecruitment to inflammatory sitesGlycoRNARNAMurine neutrophilsFunctional significanceNeutrophil recruitmentNeutrophil recruitment to inflammatory sitesBiological importanceCellsNeutrophil adhesionReduced neutrophil adhesionHomologyGlycansGenesInflammatory sitesRecruitmentEndothelial cellsPhase II Study of Peri-operative Modified FOLFIRINOX in Localized Pancreatic Ductal Adenocarcinoma
Cecchini M, Salem R, Robert M, Czerniak S, Rajaei M, Townsend J, Blaha O, Zelterman D, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan SA, Cha C, Billingsley K, Kunstman J, Chowdhury S, Tseng R, Mauricio C, Yugawa D, Escobar-Hoyos L, Johung K, Wiess C, Spickard C, Aushev V, Laliotis G, Jurdi A, Liu M, Lacy JA. Phase II Study of Peri-operative Modified FOLFIRINOX in Localized Pancreatic Ductal Adenocarcinoma. In press at JAMA Oncology 2024.Peer-Reviewed Original Research In PressProlonged length of stay and omission of adjuvant therapy are associated with early mortality after pancreatic adenocarcinoma resection
Ying L, Ilaga-Ying, Kunstman J, Peters N, Almeida M, Blackburn H, Ferrucci L, Billingsley K, Khan SA, Chhoda A, John N, Salem R, Sharma A, Ahuja N. Prolonged length of stay and omission of adjuvant therapy are associated with early mortality after pancreatic adenocarcinoma resection. In press at Surgical Oncology Insight 2024.Peer-Reviewed Original Research In PressPrecision Oncology in Gastrointestinal and Colorectal Cancer Surgery
McDonald H, Kerekes D, Kim J, Khan SA. Precision Oncology in Gastrointestinal and Colorectal Cancer Surgery. In press at Surgical Oncology Clinics of North America. 2024Peer-Reviewed Original Research
2023
Perfluorooctanesulfonic Acid and Perfluorooctanoic Acid Promote Migration of Three-Dimensional Colorectal Cancer Spheroids
Zheng J, Sun B, Berardi D, Lu L, Yan H, Zheng S, Aladelokun O, Xie Y, Cai Y, Pollitt K, Khan S, Johnson C. Perfluorooctanesulfonic Acid and Perfluorooctanoic Acid Promote Migration of Three-Dimensional Colorectal Cancer Spheroids. Environmental Science And Technology 2023, 57: 21016-21028. PMID: 38064429, DOI: 10.1021/acs.est.3c04844.Peer-Reviewed Original ResearchConceptsColorectal cancerFatty acid β-oxidationCell linesSW48 cell linesSynthesis of proteinsProgression of CRCMigration phenotypeCRC cell linesEpithelial-mesenchymal transitionThree-dimensional spheroidsMetabolic pathwaysN-cadherinΒ-oxidationMechanism of actionNovel insightsE-cadherinBiological techniquesPromotes MigrationColorectal cancer spheroidsMigration assaysMetabolic profilingKRAS G12APerfluorooctanoic acidPersistent environmental contaminantsMetabolic profileRole of colectomy in the management of appendiceal tumors: a retrospective cohort study
Marks V, Kerekes D, Butensky S, Ahuja N, Johnson C, Turaga K, Khan S. Role of colectomy in the management of appendiceal tumors: a retrospective cohort study. BMC Gastroenterology 2023, 23: 398. PMID: 37978348, PMCID: PMC10655451, DOI: 10.1186/s12876-023-03019-4.Peer-Reviewed Original ResearchConceptsGoblet cell adenocarcinomaNon-mucinous adenocarcinomaRight hemicolectomyStage 2 diseaseNeuroendocrine neoplasmsTumor typesAppendiceal tumorsMucinous adenocarcinomaAppendiceal goblet cell adenocarcinomaRole of colectomyNational Cancer DatabasePostoperative hospital stayRetrospective cohort studyRisk-adjusted analysisRange of histologiesDifferent tumor typesConclusionsMost patientsHospital stayUnplanned readmissionCohort studySurgical treatmentHistologic typeSurgical outcomesCell adenocarcinomaCancer DatabaseMulti-omic analysis reveals metabolic pathways that characterize right-sided colon cancer liver metastasis
Morris M, Jain A, Sun B, Kurbatov V, Muca E, Zeng Z, Jin Y, Roper J, Lu J, Paty P, Johnson C, Khan S. Multi-omic analysis reveals metabolic pathways that characterize right-sided colon cancer liver metastasis. Cancer Letters 2023, 574: 216384. PMID: 37716465, PMCID: PMC10620771, DOI: 10.1016/j.canlet.2023.216384.Peer-Reviewed Original ResearchConceptsLiver metastasesColon cancer liver metastasisCancer liver metastasesSided colon cancerSubset of patientsGrowth factor betaMulti-omics analysisFatty acid oxidationMetastatic diseaseInferior survivalClinical differencesClinical behaviorUntargeted metabolomics analysisTumor behaviorColon cancerBile acidsTumor cell metabolismFactor betaPatientsMetastasisPI3K-AktReactive oxygen speciesMEK-ERKLiquid chromatography-mass spectrometryRCC